Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...
‘Back the blue?’: Wall Street Journal drags Trump over Jan. 6 pardons
The Wall Street Journal editorial board tore into President Donald Trump for pardoning the rioters who attacked the Capitol ...
Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
The pharmaceutical company’s latest earnings exceeded Wall Street’s expectations as it braces for one of its top-selling ...
Wall St set for higher open after Netflix results, Trump's AI investment plans
Wall Street's main indexes were set to open higher on Wednesday, with the tech-heavy Nasdaq leading gains, as investors ...
Wall Street Lunch: AI Project Stargate A Go
Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...
Balanced Expectations Amid Challenges and Opportunities for Johnson & Johnson: Hold Rating Issued
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
24/7 Wall St. on MSN3h
The Stock Market Is Overbought and Insiders Are Selling - Grab These 5 High-Yield Blue Chips Now
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...
J&J Tops Quarterly Profit Estimates on Cancer Drug Sales
Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...
Morningstar5d
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Medical-technology and drug company's 2025 sales outlook is below consensus Johnson & Johnson's stock ... from Dow Jones Newswires and The Wall Street Journal. We sell different types of products ...